Citations

Mayo Clinic

Clear

300 citation(s) found for "Ma, Cindy S".

Abstract 3427: Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study
Richardson, Michaela , Roesler, Michelle A. , Hirsch, Betsy , Cioc, Adina, Warlick, Erica D. , Poynter, Jenny N. , Blair, Cindy K. , Nguyen, Phuong , Cerhan, James R.

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3427-3427

10.1158/1538-7445.am2016-3427 Get It

Abstract Background Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders that result in ineffective hematopoiesis. Individuals with MDS have a high risk of progressing to leukemia, with approximately 30% expected to develop acute myeloid leukemia (AML). Benzene exposure is one of the few well-established risk factors for AML, and recent studies suggest it is also a risk factor for MDS. Exposure to other occupational and residential chemicals has been inconsistently associated with hematologic malignancies. In this analysis, we evaluated occupational and residential chemical exposures as risk factors for AML and MDS using population-based data. Methods AML and MDS cases were identified by rapid case ascertainment through the Minnesota Cancer Surveillance System (MCSS). Centralized pathology and cytogenetics reviews were conducted to confirm diagnosis and classify by subtypes. Controls were identified through the Minnesota State driver's license/identification card list. Chemical exposures were measured by self-report and included occupational and residential exposure to a variety of chemicals. Unconditional logistic regression with adjustment for age, sex, previous cancer treatment, income, and farm or rural residence was used to calculate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CI). Smoking, obesity and physical activity were considered as potential confounders but did not change effect estimates by 10% or more. Results We included 265 MDS cases, 420 AML cases, and 1388 controls in this analysis. As expected, we observed significant associations between benzene and both MDS and AML (OR = 1.77, 95% CI 1.17, 2.67 and OR = 2.03, 95% CI 1.45, 2.83, respectively). Exposure to vinyl chlorides was associated with MDS (OR = 2.25, 95% CI 1.32, 3.81) but not with AML (OR = 1.36, 95% CI 0.83, 2.21). Exposure to fertilizers (OR = 1.70, 95% CI 1.11, 2.59), soot (OR = 2.64, 95% CI 1.59, 4.39), creosote (OR = 1.95, 95% CI 1.08, 3.51), inks, dyes and tanning solutions (OR = 1.63, 95% 1.02, 2.60), and coal dust (2.64, 95% CI 1.30, 5.39) were associated with AML, while no association was seen between any of these exposures and MDS (range ORs = 0.78-1.25). No significant associations were observed for occupational pesticide exposures in either group. Discussion These data confirm the importance of benzene as a risk factor for myeloid malignancy and provide risk estimates in a population-based sample. A number of other significant associations with occupational and residential chemicals were observed for AML; however, all exposures were reported by only a small percentage of cases (≤10%). While chemical exposures play a clear role in the etiology of myeloid malignancy, these exposures do not account for the majority of cases. Citation Format: Jenny N. Poynter, Michaela Richardson, Michelle Roesler, Cindy K. Blair, Betsy Hirsch, Phuong Nguyen, Adina Cioc, James R. Cerhan, Erica Warlick. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3427.
Health Systems Science Curricula in Undergraduate Medical Education: Identifying and Defining a Potential Curricular Framework
Gonzalo, Jed D. , Dekhtyar, Michael , Starr, Stephanie R. , Borkan, Jeffrey , Brunett, Patrick, Fancher, Tonya L. , Grethlein, Sara J., Lai, Cindy J. , Lawson, Luan , Monrad, Seetha U. , Schwartz, Mark D. , Skochelak, Susan E., Green, Jennifer Greif , O’Sullivan, Patricia , Fancher, Tonya L , Monrad, Seetha U

Academic Medicine | April 19, 2016 | Volume: 92 | Issue: 1 | Pages: 123-131

10.1097/acm.0000000000001177 | PMID 27049541 Get It

Purpose The authors performed a review of 30 Accelerating Change in Medical Education full grant submissions and an analysis of the health systems science (HSS)-related curricula at the 11 grant recipient schools to develop a potential comprehensive HSS curricular framework with domains and subcategories. Method In phase 1, to identify domains, grant submissions were analyzed and coded using constant comparative analysis. In phase 2, a detailed review of all existing and planned syllabi and curriculum documents at the grantee schools was performed, and content in the core curricular domains was coded into subcategories. The lead investigators reviewed and discussed drafts of the categorization scheme, collapsed and combined domains and subcategories, and resolved disagreements via group discussion. Results Analysis yielded three types of domains: core, cross-cutting, and linking. Core domains included health care structures and processes; health care policy, economics, and management; clinical informatics and health information technology; population and public health; value-based care; and health system improvement. Cross-cutting domains included leadership and change agency; teamwork and interprofessional education; evidence-based medicine and practice; professionalism and ethics; and scholarship. One linking domain was identified: systems thinking. Conclusions This broad framework aims to build on the traditional definition of systems-based practice and highlight the need for medical and other health professions schools to better align education programs with the anticipated needs of the systems in which students will practice. HSS will require a critical investigation into existing curricula to determine the most efficient methods for integration with the basic and clinical sciences.
Vascular Toxicities of Cancer Therapies
Herrmann, Joerg , Yang, Eric H. , Iliescu, Cezar , Charitakis, Konstantinos, Hakeem, Abdul , Toutouzas, Konstantinos , Leesar, Massoud A. , Marmagkiolis, Konstantinos , Iliescu, Cezar A, Cilingiroglu, Mehmet , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Circulation | March 28, 2016 | Volume: 133 | Issue: 13 | Pages: 1272-1289

10.1161/circulationaha.115.018347 | PMID 27022039 Get It

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.
En bloc resection of a C-1 lateral mass osteosarcoma: technical note
Cloft, Harry J. , Segura, Leal G. , Hill, Cindy A., Browning, Meghen B., Brandt, Jon M., Lew, Sean M. , Foy, Andrew , Clarke, Michelle J. , Price, Daniel L.

Journal of Neurosurgery: Pediatrics | March 11, 2016 | Volume: 18 | Issue: 1 | Pages: 46-52

10.3171/2015.12.peds15496 | PMID 26966885 Get It

Osteosarcoma is an aggressive primary bone tumor. It is currently treated with multimodality therapy including en bloc resection, which has been demonstrated to confer a survival benefit over intralesional resection. The authors present the case of an 8-year-old girl with a C-1 lateral mass osteosarcoma, which was treated with a 4-stage en bloc resection and spinal reconstruction. While technically complex, the feasibility of en bloc resection for spinal osteosarcoma should be explored in the pediatric population.
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora, Shilpkumar , Panaich, Sidakpal , Patel, Nilay , Patel, Nileshkumar , Lahewala, Sopan , Thakkar, Badal, Savani, Chirag, Jhamnani, Sunny , Singh, Vikas , Patel, Nish , Patel, Samir , Sonani, Rajesh, Patel, Achint , Deshmukh, Abhishek , Chothani, Ankit , Bhatt, Parth , Mohamad, Tamam , Remetz, Michael S., Curtis, Jeptha P. , Attaran, Ramak R., Mena, Carlos, Schreiber, Theodore , Cleman, Michael , Forrest, John K. , Badheka, Apurva O., Tripathi, Byomesh , Patel, Jay N. , Grines, Cindy L. , Panaich, Sidakpal S

Catheterization and Cardiovascular Interventions | February 25, 2016 | Volume: 88 | Issue: 4 | Pages: 605-616

10.1002/ccd.26452 | PMID 26914274 Get It

ObjectiveThe aim of our study was to study the impact of glycoprotein IIb/IIIa inhibitors (GPI) on in‐hospital outcomes.BackgroundThere is paucity of data regarding the impact of GPI on the outcomes following peripheral endovascular interventions.MethodsThe study cohort was derived from Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database between the years 2006 and 2011. Peripheral endovascular interventions and GPI utilization were identified using appropriate ICD‐9 Diagnostic and procedural codes. Two‐level hierarchical multivariate mixed models were created. The study outcomes were: primary (in‐hospital mortality and amputation studied separately) and secondary (composite of in‐hospital mortality and postprocedural complications). Hospitalization costs were also assessed.ResultsGPI utilization (OR, 95% CI, P‐value) was independently predictive of lower amputation rates (0.36, 0.27–0.49, <0.001). There was no significant difference in terms of in‐hospital mortality (0.59, 0.31–1.14, P 0.117), although GPI use predicted worse secondary outcomes (1.23, 1.03–1.47, 0.023). Following propensity matching, the amputation rate was lower (3.2% vs. 8%, P < 0.001), while hospitalization costs were higher in the cohort that received GPI ($21,091 ± 404 vs. 19,407 ± 133, P < 0.001).ConclusionsMultivariate analysis revealed GPI use in peripheral endovascular interventions to be suggestive of an increase in composite end‐point of in‐hospital mortality and postprocedural complications, no impact on in‐hospital mortality alone, significantly lower rate of amputation, and increase in hospitalization costs. © 2016 Wiley Periodicals, Inc.
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Dorsey, E. Ray , Achey, Meredith A. , Beck, Christopher A. , Beran, Denise B., Biglan, Kevin , Boyd, Cynthia M. , Schmidt, Péter , Simone, Richard, Willis, Allison W. , Galifianakis, Nicholas B. , Katz, Maya , Dodenhoff, Kristen A. , Ziman, Nathan, Aldred, Jason , Carter, Julie, Jimenez‐Shahed, Joohi , Hunter, Christine , Spindler, Meredith , Morgan, John C. , McLane, Dedi, Hickey, Patrick , Gauger, Lisa, Richard, Irene Hegeman, Bull, Michael, Mejia, Nicte I. , Bwala, Grace, Nance, Martha , Shih, Ludy C. , Anderson, Lauren , Singer, Carlos , Zadikoff, Cindy , Okon, Natalia, Feigin, Andrew, Ayan, J., Vaughan, Christina , Cooper, Jessica , Webb, S. J., Dhall, Rohit , Hassan, Anhar , Weis, Delana, DeMello, Steven, Smith, Joseph M. , Keenan, H. Tait, Korn, Ryan, Schwarz, Heidi B., Stevenson, E. Anna , Zhu, William , Tanner, Caroline M. , Mari, Zoltan K. , Pahwa, Rajesh , Riggare, Sara S. , Wicks, Paul J , Sharma, Saloni , Jimenez-Shahed, Joohi

Telemedicine and e-Health | February 17, 2016 | Volume: 22 | Issue: 7 | Pages: 590-598

10.1089/tmj.2015.0191 | PMID 26886406 Get It

Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.
SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiolog
Iliescu, Cezar , Herrmann, Joerg , Yang, Eric H. , Charitakis, Konstantinos, Hakeem, Abdul , Tοutouzas, Konstantinos, Leesar, Massoud A. , Marmagkiolis, Konstantinos , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Catheterization and Cardiovascular Interventions | January 13, 2016 | Volume: 87 | Issue: 5 | Pages: No page available

10.1002/ccd.26379 | PMID 26756277 Get It

In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients. © 2016 Wiley Periodicals, Inc.
Intravascular Ultrasound in Lower Extremity Peripheral Vascular Interventions
Panaich, Sidakpal , Arora, Shilpkumar , Patel, Nilay , Patel, Nileshkumar , Savani, Chirag, Patel, Achint , Thakkar, Badal, Singh, Vikas , Patel, Nish , Agnihotri, Kanishk, Bhatt, Parth , Deshmukh, Abhishek , Gupta, Vishal , Attaran, Ramak R., Mena, Carlos, Cleman, Michael , Forrest, John K. , Badheka, Apurva O., Patel, Samir , Grines, Cindy L. , Panaich, Sidakpal S

Journal of Endovascular Therapy | December 26, 2015 | Volume: 23 | Issue: 1 | Pages: 65-75

10.1177/1526602815620780 | PMID 26637836 Get It

Purpose: To examine the impact of intravascular ultrasound (IVUS) utilization during lower limb endovascular interventions as regards postprocedural complications and amputation. Methods: The study cohort was derived from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database between the years 2006 and 2011. Peripheral endovascular interventions were identified using appropriate ICD-9 procedure codes. Two-level hierarchical multivariate mixed models were created. The co-primary outcomes were in-hospital mortality and amputation; the secondary outcome was postprocedural complications. Model results are given as the odds ratio (OR) and 95% confidence interval (CI). Hospitalization costs were also assessed. Results: Overall, among the 92,714 patients extracted from the database during the observation period, IVUS was used in 1299 (1.4%) patients. IVUS utilization during lower extremity peripheral vascular procedures was independently predictive of a lower rate of postprocedural complications (OR 0.80, 95% CI 0.66 to 0.99, p=0.037) as well as lower amputation rates (OR 0.59, 95% CI 0.45 to 0.77, p<0.001) without any significant impact on in-hospital mortality. Multivariate analysis also revealed IVUS utilization to be predictive of a nonsignificant increase in hospitalization costs ($1333, 95% CI −$167 to +$2833, p=0.082). Conclusion: IVUS use during lower limb endovascular interventions is predictive of lower postprocedural complication and amputation rates with a nonsignificant increase in hospitalization costs.
SCAI expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Interven
Iliescu, Cezar , Herrmann, Joerg , Yang, Eric H. , Charitakis, Konstantinos, Hakeem, Abdul , Tοutouzas, Konstantinos, Leesar, Massoud A. , Marmagkiolis, Konstantinos , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Catheterization and Cardiovascular Interventions | December 23, 2015 | Volume: 87 | Issue: 5 | Pages: 895-899

10.1002/ccd.26375 | PMID 26700403 Get It

In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients. © 2015 Wiley Periodicals, Inc.
Transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with cirrhosis
Thakkar, Badal, Patel, Aashay, Mohamad, Bashar, Patel, Nileshkumar , Bhatt, Parth , Bhimani, Ronak , Patel, Achint , Arora, Shilpkumar , Savani, Chirag, Solanki, Shantanu , Sonani, Rajesh, Patel, Samir , Patel, Nilay, Deshmukh, Abhishek , Mohamad, Tamam , Cleman, Michael , Mangi, Abeel A. , Forrest, John K. , Badheka, Apurva O., Grines, Cindy L.

Catheterization and Cardiovascular Interventions | December 23, 2015 | Volume: 87 | Issue: 5 | Pages: 955-962

10.1002/ccd.26345 | PMID 26699085 Get It

ObjectivesTo compare the in‐hospital outcomes in cirrhosis patients undergoing transcatheter aortic valve replacement (TAVR) versus those undergoing surgical aortic valve replacement (SAVR).BackgroundOver the last 10 years, TAVR has emerged as a therapeutic option for treating severe aortic stenosis in high‐risk patients. Cirrhosis patients have a high risk of operative morbidity and mortality while undergoing cardiac surgery. This study's hypothesis was that TAVR is a safer alternative compared to SAVR in cirrhosis patients.MethodsThe study population was derived from the National Inpatient Sample (NIS) for the years 2011–2012 using ICD‐9‐CM procedure codes 35.21 and 35.22 for SAVR, and 35.05 and 35.06 for TAVR. Patients <50 years of age and those who concomitantly underwent other valvular procedures were excluded. ICD‐9‐CM diagnosis codes were used to identify patients with liver cirrhosis, portal hypertension, and esophageal varices. Using propensity score matching, two matched cohorts were derived in which the outcomes were compared using appropriate statistical tests.ResultsThere were 30 patients in the SAVR and TAVR group each. Compared to the TAVR group, the patients in SAVR group had significantly higher rate of transfusion of whole blood or blood products (p = 0.037), longer mean postprocedural length of stay (p = 0.006), and nonsignificantly higher mean cost of hospitalization (p = 0.2), any complications rate (p = 0.09), and liver complications rate (p = 0.4). In‐hospital mortality rate was same in the both the groups. No patients in the TAVR group required open‐heart surgery or cardiopulmonary bypass.ConclusionTAVR could be a viable option for aortic valve replacement in cirrhosis patients. © 2015 Wiley Periodicals, Inc.